Dean Pellin-Ruse
CEO
Replay available
Novacyt S.A. (NCYT) Q2 2026 Earnings Call
Novacyt S.A. (LSE: NCYT) Q2 2026 earnings conference call, held 2026-09-30. Replay captured from the company's public earnings webcast.
Investor webinar replay
Meeting Overview The Novosight Group investor presentation provided an update on the company's interim results, highlighting significant operational achievements, financial performance, and strategic initiatives. Key topics included the acquisition of Southern Cross Diagnostics, the launch of a new assay, company restructuring efforts, and a collaboration agreement with Illumina. Key Discussion Points - Overview of Novosight Group's business and core markets: reproductive healthcare, precision medicine, and infectious disease. - Acquisition of Southern Cross Diagnostics and its contribution to revenue growth. - Launch of the Your Gene Insight DPYD assay for chemotherapy patients. - Company restructuring aimed at reducing operational expenses. - Signing of a five-year master collaboration agreement with Illumina for technical and operational collaboration. - Financial highlights including revenue growth, gross profit margins, and cash flow status. Decisions Made - No explicit decisio...
Featured Presenters
Replay transcript excerpt
Speaker 1: Good morning and welcome to the Novosight Group investor presentation. Throughout this recorded presentation, investors will be in listening mode. Questions are encouraged and can be submitted at any time by the Q&A tab situated on the right-hand corner of your screen. Simply type in your questions and press send. I'd now like to welcome our French shareholders. Speaker 2: Your questions are encouraged and can be submitted at any time via the Q&A tab. Speaker 2: You just have to grab your questions and click on Send. Speaker 2: For those who wish to access the translation in French, Speaker 2: please select Speaker 2: the subtitle icon located on the right side of the screen. Speaker 2: Before we begin, Speaker 2: I would like to submit the following survey to you. Speaker 2: I would now like to give the floor to the management team. Hello. Speaker 1: And now at that time, Jay Tenenbreeze, Speaker 1: CEO, good morning, sir. Speaker 3: Thank you very much, and good morning, everyone. And thank you for joining us this morning for our interim results presentation. Speaker 3: Hopefully, by now, Steve and I are faces that are familiar to everyone on this call. Speaker 3: And as your CEO and CFO, we're very much looking forward to sharing another 6 months progress Speaker 3: that Novacife has made over another busy but effective 6 months period. Speaker 3: Just before We dive into the results, a quick recap on who we are as a business. Speaker 3: We're an international molecular diagnostics company Speaker 3: with a growing portfolio of clinical assays, tests that are running the market, Speaker 3: instrumentation Speaker 3: that is used to run samples and those tests and research tools. Speaker 3: Our 3 core markets are in reproductive healthcare, Speaker 3: pr...